Europe

Health Policy Funding, Hopes at Odds in EU

August 07, 2020

Budget battle threatens efforts to bolster Europe’s pharma strategy.

EU Medical Device Supply Chains and Trade Agreements: The COVID-19 Response

August 02, 2020

ByAndrew Hood and Cliodhna McDonough

Andrew Hood and Cliodhna McDonough look at the key issues necessary to support business and the community in developing a long-term and sustainable response to the challenges highlighted by COVID-19.

Is Drug Production Heading Back to Europe From Abroad?

July 09, 2020

ByReflector

Pharmaceutical Executive

Pandemic sparks call for European manufacturing renaissance.

The Specter of Compulsory Licensing Haunts Vaccine Debate

June 11, 2020

ByReflector

Industry prospects at mercy of public discourse, policy shifts.

A New, Less Friendly Normal Looms for European Drugmakers

May 10, 2020

ByReflector

Pharmaceutical Executive

Pandemic fallout could spell fundamental business and policy shifts.

Getting through the EU MDR and IVDR Whirlwind: Steps to Compliance

March 11, 2020

ByReflector

Medical devices manufacturers and pharma companies alike should review their compliance strategies as the EU Medical Device Regulation Date of Application approaches.

Blood Feud Divides Europe Over Plasma Shortfalls

March 09, 2020

ByReflector

Pharmaceutical Executive

The collection of source plasma for new therapies igniting debate.

Does the UK Medicines and Medical Devices Bill Provide Post-Brexit Certainty?

March 02, 2020

ByCliodhna McDonough

The Medicines and Medical Devices Bill was recently introduced to the UK House of Commons. Does it provide the confidence that the UK is still a leading country for life sciences? Cliodhna McDonough reports.

Unlocking the Black Box of Pharma Pricing in Europe

February 09, 2020

ByReflector

Pharmaceutical Executive

New OECD study doesn’t shed much light on the effectiveness of managed entry agreements for drug access.

Exploiting EMA’s Medicines Database to Full Effect

January 14, 2020

ByRemco Munnik

Goals for IDMP in Europe must not be diluted in 2020, if standardized medicinal product data is to be of tangible real-world benefit, says Remco Munnik.